ADC successes in early-line breast cancer via combinations

This week’s short list of positive clinical outcomes includes data that brought antibody-drug conjugates two steps closer to their next frontier: combination regimens in frontline cancer treatment.

Gilead Sciences Inc. (NASDAQ:GILD) reported that Trodelvy sacituzumab govitecan, when combined with Keytruda pembrolizumab, improved progression-free survival (PFS) in the Phase III ASCENT-04 trial, compared with Keytruda plus chemotherapy, in PD-L1-positive, previously untreated metastatic triple-negative breast cancer...